Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Asan Medical Center, University of Ulsan, Ulsan College, Kaohsiung Medical University, National Cheng Kung University Hospital, National Health Research Institutes, Kaohsiung Medical University Chung-Ho Memorial Hospital, Seoul National University, Seoul National University Hospital, Korea University, Dong-A University Hospital, Yonsei University Health System, Seoul National University Bundang Hospital, Osaka International Cancer Institute, National Cancer Center Hospital East, Saitama Medical University, Chonnam National University Hwasun Hospital, Japanese Foundation For Cancer Research, The Cancer Institute Hospital, Gachon University Gil Medical Center, Aichi Cancer Center, Ishikawa Prefectural Central Hospital, Chang Gung University, Linkou Chang Gung Memorial Hospital, China Medical University Hospital, China Medical University, Hiroshima City Asa Citizens Hospital, Kobe City Medical Center General Hospital, Ono Pharmaceutical (Japan)